Clinical trials reveal promising alternatives to high-toxicity tuberculosis drug

Clinical trials reveal promising alternatives to high-toxicity tuberculosis drug

Publication date: Jul 10, 2025

These results position delpazolid as a promising alternative to linezolid for future TB treatment regimenspending confirmation in larger studies. “Despite its effectiveness, linezolid is simply too toxic for many patients. Editors have highlighted the following attributes while ensuring the content’s credibility:Scanning electron micrograph of Mycobacterium tuberculosis bacteria, which cause TB. Without the collaboration within PanACEA, this would not have been possible in such a short time. This article has been reviewed according to Science X’s editorial process and policies . It highlights the importance of tackling TB as a global community. “

Concepts Keywords
Munich Clinical
Mycobacterium Combination
Therapy Delpazolid
Tropical Dose
Drug
Drugs
Findings
Linezolid
Panacea
Patients
Promising
Sutezolid
Tb
Treatment
Trials

Semantics

Type Source Name
drug DRUGBANK Linezolid
disease MESH Infectious Diseases
disease IDO role
disease MESH Infection
drug DRUGBANK Bedaquiline
drug DRUGBANK Pretomanid
drug DRUGBANK Moxifloxacin
disease MESH anemia
drug DRUGBANK Spinosad
drug DRUGBANK Delamanid
disease IDO blood
drug DRUGBANK Tropicamide
drug DRUGBANK Sutezolid
disease IDO bacteria
disease IDO process
disease MESH tuberculosis
pathway KEGG Tuberculosis

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *